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Objective: Patients’ expectations about the benefit of an intervention are important
determinants of the placebo effect. Little is known about the extent to which expectations
influence outcomes of treatments in the field of appetite regulation. This study aimed
to investigate the effects of treatment-related expectations on subjective and objective
markers of appetite.
Methods: 90 healthy participants of normal weight were randomly allocated to either
an appetite-enhancing placebo group, a satiety-enhancing placebo group, or a control
group. All participants received a placebo capsule along with group-specific verbal
suggestions to either be appetite-promoting, or satiety-enhancing, or to have no effect on
appetite. Before and during the 2 h following randomization, participants were repeatedly
asked to rate feelings of hunger and satiety on visual analog scales (VAS), and blood
samples were taken repeatedly to assess plasma ghrelin levels as a physiological marker
of hunger.
Results: In comparison to the control group, the satiety-enhancing placebo intervention
significantly reduced appetite and increased satiety. The appetite-enhancing placebo
intervention did not alter subjective levels of hunger, but increased plasma ghrelin levels
in females.
Conclusions: Results provide the first experimental evidence that appetite-regulating
placebo interventions can elicit a psychobiological response. Expectations are important
factors to consider when evaluating the effects of interventions in the field of appetite
regulation.
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INTRODUCTION
Obesity is a dramatically increasing problem in our society. Treatment approaches for obesity
include psychological, pharmacological, and surgical interventions (1–3). To what extent placebo
effects, i.e. positive treatment expectations, contribute to the success of obesity treatments is
unclear. A recent systematic review of placebo-controlled surgery trials revealed that patients
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receiving sham bariatric surgery showed on average 71% of the
weight loss reported by the patients in the active surgery groups
(4). These data suggest a strong inhibitory effect of placebo
interventions on appetite.
Eating behavior is closely linked to mental sets. For example,
Higgs (5) reported that participants consumed less in a test
session when they were reminded of a recent meal. Furthermore,
Provencher et al. (6) showed that participants ate less when
the meal was perceived as healthy. Crum and colleagues went
one step further and evaluated the impact of expectations on
plasma levels of the gut hormone ghrelin, a physiological marker
of appetite (7). In a within-subjects design, healthy volunteers
on two occasions were made believe to receive either a “high-
caloric, indulgent milk shake” or a “low-caloric, sensitive milk
shake.” In truth, both milk shakes were of identical contents.
Results showed a different ghrelin response to these milk shakes:
In comparison to the “sensible” shake, the ghrelin increase was
larger when expecting the “indulgent” milk shake, followed by a
sharper decline of ghrelin levels 30min after drinking the shake.
These findings indicate a strong impact of nutrition-specific
expectations on appetite and satiety, as evidenced by altered
plasma ghrelin levels before and after a test meal. Additionally,
differences in eating behavior are linked to gender. Several studies
have shown that females tend to eat healthier than men [i.e.,
avoiding high-fat food and eating more fruit and fiber; (8, 9)].
This has been linked to more concerns of women about their
body weight as compared to men (10). Also, it has been reported,
that females eat more sweets when perceiving stress than men
(11).
In this study, we investigated whether treatment-related
expectations can affect appetite, satiety and plasma ghrelin
levels. In a between-subjects design, normal-weight participants
received a placebo capsule together with the information that
its content would either increase appetite, or increase satiety,
or would leave appetite and satiety unaffected. We hypothesized
that the appetite-enhancing placebo intervention would decrease
satiety and increase appetite and plasma ghrelin levels, while the
satiety-enhancing placebo intervention would have the opposite
effects, both in comparison to a no treatment control group.
MATERIALS AND METHODS
Participants
The study was conducted at the Institute of Medical Psychology
at the LMU Munich, Germany. Healthy participants aged 18–36
years were recruited via flyers and a university mailing list. All
participants had to be of normal weight (Body Mass Index (BMI)
18–25 kg/m2). Exclusion criteria included report of pregnancy,
breastfeeding, regular use of medication (except hormonal
contraceptives and anti-allergic drugs), acute or chronic disease,
smoking, surgery in the last 4 weeks before the experiment,
elevated fasting blood glucose levels (>100 mg/dl), and elevated
levels of anxiety and/or depression scores [>7 in at least one
subscale of the Hospital Anxiety and Depression Scale (HADS);
(12)]. The study protocol was approved by the ethics committee
of the Medical Faculty at LMU Munich. Participants provided
written informed consent and received 45 Euro compensation.
Experimental Procedure
Ninty participants were randomly allocated to one of three
groups: “control,” “enhanced appetite” (placebo), or “enhanced
satiety” (placebo). To allow for double-blinding, 6 additional
participants were randomized to verum treatments (3 enhanced
appetite, 3 enhanced satiety; compare (13); Figure 1). Groups
were stratified by sex due to sex differences in eating behavior
(14) and neurobiological mechanisms of placebo effects (15).
At recruitment, participants were informed that the experiment
investigated how biological and psychological factors contribute
to the regulation of hunger and appetite.
Participants underwent a single test session starting at 8
o’clock in the morning. They were asked to abstain from food
for 10–12 h prior to the experiment (intake of small amounts
of water was allowed). Upon arrival, participants took seat in
a comfortable chair, and blood glucose levels were determined
from finger blood samples using a BG Star device (Sanofi-
Aventis, Hannover, Germany). An indwelling flexible catheter
was then placed in the antecubital vein and kept patent with
a saline infusion to allow for repeated blood drawing during
the experiment. Electrodes to measure the electrocardiogram
(ECG) were attached. Participants were then asked to fill in
the “Hospital Anxiety and Depression Scale” [HADS; (12)], the
‘Three Factor Eating Questionnaire’ [TFEQ; (16)] and to rate
current levels of hunger and satiety on 100-mm visual analog
scales (VAS). Thereafter, the first blood sample to assess ghrelin
levels was collected and the ECG measurement was started.
Following a 15-min baseline period, the experimenter opened
the randomization envelope, performed the verbal expectancy
manipulation according to group allocation (“appetite increase,”
“satiety increase,” or “control”) and asked the participants to
swallow the provided test capsule with 100ml of mineral water
(standardized temperature of 20◦C). After resting periods of 30
and 60min, respectively, participants were asked to rate current
levels of hunger and satiety, and the second and third blood
sample for ghrelin assessments were collected.
Blinding and Randomization
A person not directly involved in the experiments prepared an
opaque, sequentially-numbered randomization envelope for each
participant according to a computer-generated randomization
list. The envelopes contained information on the type of
intervention (“appetite-stimulating,” “satiety-enhancing,” or
“control”) as well as a test capsule. Neither the experimenter
nor the participants were informed whether the capsule in
the hunger-enhancing and satiety-enhancing conditions was
a placebo or contained an active ingredient (double-blinded
design).
Capsules
Identical white and opaque vegetarian capsules were used for
all interventions. The placebo capsules were filled with lactose
(Heirler Cenovis GmbH, Radolfzell, Germany). For the satiety-
increasing active intervention, capsules were filled with an
alginate complex (lyophilized sodium-alginate complex, added
with aluminum- and calciumchoride; CM3 Alginat Kapseln,
Easyway GmbH, Monheim, Germany). Alginate reduces hunger
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FIGURE 1 | Study design. This randomized, double-blind, controlled trial was conducted in a between-subject design. After the baseline measurement, participants
were randomly allocated to one of five groups (“control,” “placebo enhanced appetite,” “placebo enhanced satiety,” “verum enhanced appetite,” and “verum
enhanced satiety”). The verum groups served only for double-blinding and were not evaluated further.
and increases satiety feelings, which is partly due to its volume-
increasing content (17). For the appetite-stimulating active
intervention, one tablet of “Appetit-Anreger” with extracts of
bitter herbs (Zirkulin Naturheilmittel GmbH, Bremen) was
placed in the study capsules. Dietary supplements containing
bitters are traditionally used to increase appetite and to support
digestion (18).
Expectancy Manipulation
Standardized expectancy manipulations were performed by two
female experimenters in white coats (one undergraduate, one
graduate student). After opening the randomization envelopes,
participants in the appetite-stimulating groups were told to
receive either a placebo capsule or a capsule filled with
bitters, and that bitters are known to increase secretion of
digestive fluids in the stomach and thus are expected to
increase appetite within 20–30min after intake of the capsule.
Participants in the satiety-enhancing groups were told to receive
either a placebo capsule or a capsule containing alginate,
and that alginate is known to increase its volume in the
stomach and thus is expected to enhance satiety within 20–
30min after intake of the capsule. They were told to receive
either a verum or a placebo intervention (randomization
ratio was not disclosed). Participants in the control group
received a placebo capsule together with the information that
its ingredients would have no effect on gastric activity and
appetite.
Measurements
Hunger and Satiety Ratings
Perceived hunger (“How hungry do you feel?”) was rated using
a 100-mm visual analog scale from “0” (“not at all hungry”) to
“100” (“extremely hungry”). Perceived satiety (“How full do you
feel?”) were assessed by means of a 100-mm visual analog rating
scale, ranging from 0 (“not at all full”) to 100 (“extremely full”).
Plasma Ghrelin
To assess the concentration of ghrelin in plasma, blood
samples were collected in commercially available EDTA
tubes (2.7ml), complemented with 54 µl 4mM 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF)
(19). Blood samples were immediately stored on ice and
centrifuged within 30min for 10min at 3,000 g and 4◦C. Two
samples of 500 µl plasma were transferred to Eppendorf tubes
and complemented with 100 µl 1mM HCl. Samples were
gently mixed and stored at −70◦C until final analysis. Analysis
of plasma ghrelin content was performed with the Ghrelin
(total) Assay Kit (Catalogue number: EZGRT-89K) from Merck
Millipore, Darmstadt, Germany according to protocol.
Electrocardiogram
The electrocardiogram was recorded to evaluate changes in heart
rate. A transient increase of heart rate has been described as part
of the cephalic phase response when food is anticipated (20).
The electrocardiogram signal was measured continuously during
the experiment using three disposable Ag/AgCl electrodes, which
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were positioned in an Einthoven Lead I configuration and
connected to the BIOPAC amplifier module ECG100C of a
BIOPAC MP 150 device (BIOPAC Systems Inc., Goleta, CA,
USA). Data was acquired using AcqKnowledge 3.7.2 software and
a sampling rate of 500Hz. Intervals between successive R peaks
(cardiac periods) were extracted from the electrocardiogram
signal using the peak-detection function implemented in
AcqKnowledge 3.7.2. Heart periods were examined and screened
for artifacts based on the procedure developed by Proges and
Byrne (21). Average heart rate was calculated for the last five
artifact-free minutes of the baseline period and the two post-
intervention periods (i.e., minutes 25–30 andminutes 55–60 after
randomization).
Questionnaires
The Hospital Anxiety and Depression scale [HADS; (12)] was
used to screen for anxiety and/or depression. The Three Factor
Eating Questionnaire [TFEQ; (16)] with its three subscales
“cognitive restraint of eating,” “disinhibition,” and “hunger” was
used to test for possible differences in eating behavior between
groups at baseline.
Female participants were asked for the normal length of
their menstrual cycle, the beginning of the last menstruation,
and whether they took hormonal contraceptives. Time point of
ovulation was estimated by subtracting 14 days from the length
of the menstrual cycle (22).
Statistical Analyses
Assuming an effect size partial eta-squared of 0.1, the study
was planned to have a power of 90% to detect a significant
interaction effect between “group” and “time point” in a mixed
ANOVA for changes of hunger, satiety and ghrelin from before
to after the intervention (with a type 1 error of 5%) (calculated
by GPower Version 3.1.7). However, we later decided to use
ANCOVAs to adjust for the slight group differences at baseline.
Statistical analyses were performed using SPSS (version 23.0).
Hunger ratings, satiety ratings and plasma ghrelin levels were
each subjected to 3-way analyses of covariance (ANCOVA), with
two levels of “time” (30min and 60min after randomization),
three levels of “group” (appetite, satiety, control) and two levels
of “sex” (male, female). In each model, baseline levels (15min
before randomization) were included as covariates. Bonferroni
corrections were applied, where appropriate. A p-value ≤ 0.05
(2-sided) was considered statistically significant.
RESULTS
Participants
One Hundred thirteen participants were assessed for eligibility
and 17 were excluded (three did not meet inclusion criteria,
12 declined to participate, one did not show up and one had
elevated fasting blood glucose levels). Thirty participants each
were assigned to the appetite group, the satiety group, and the
control group. All participants completed the experiment.
Study groups were comparable with respect to demographic
variables, eating behavior as well as anxiety and depression scores
(Table 1). Participants had a mean age of 26.6 years (3.2 SD;
range: 18–36 years) and amean BMI of 21.9 kg/m2 (1.8 SD; range:
18.6–25 kg/m2). Fourteen women were in the preovulatory phase
and two women in the postovulatory phase of the menstrual
cycle, while 29 women were using hormonal contraceptives.
Hunger Ratings
The 3-way ANCOVA for post-intervention hunger ratings,
controlled for baseline levels, revealed a significant 3-
way interaction between “group,” “time,” and “sex”
[Fgroup×time×sex(2, 83) = 4.0, p = 0.023]. However, post
hoc 2-way ANCOVAs performed separately for each sex
showed no significant interaction effect between “group”
and “time” [women, Fgroup×time(2, 41) = 3.1, p = 0.058; men,
Fgroup×time(2, 41) = 0.6, p = 0.571). Furthermore, the 3-way
ANCOVA showed a significant main effect of “group” [Fgroup
(2, 83) = 6.7, p = 0.002]. Bonferroni-corrected post hoc tests
indicated significantly lower hunger ratings in the satiety group
compared to the control group (p = 0.033) and to the appetite
group (p= 0.002) (Figure 2, Table 2).











Age (years) 23.6 (3) 23.4 (2.9) 24 (3.7) 0.243 (2.87) 0.785
Body Mass Index (kg m2) 21.8 (2) 21.7 (1.7) 22.2 (1.7) 0.632 (2.87) 0.534
Blood Glucose (mg/dl) 93.8 (8.1) 95.3 (9.9) 95.5 (6.6) 0.337 (2.84) 0.715
Hunger ratings (VAS) 4.6 (3.2) 6.3 (2.3) 5.7 (2.6) 2.867 (2.87) 0.062
Satiety ratings (VAS) 3.0 (2.2) 2.6 (2.4) 2.6 (1.9) 1.931 (2.87) 0.151
Ghrelin levels (pg/ml) 495.2 (217.3) 463.2 (180.5) 464 (212.4) 0.215 (2.87) 0.807
HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS)
Anxiety 3 (2.4) 2.8 (1.9) 3.4 (1.6) 0.560 (2.87) 0.573
Depression 1.4 (1. 5) 1.6 (1.8) 1.9 (2.1) 0.652 (2.87) 0.523
THREE FACTOR EATING QUESTIONNAIRE (TFEQ)
Cognitive Restraint of Eating 10.6 (2) 10.9 (2.2) 10.1 (2.0) 0.317 (2.87) 0.317
Disinhibition 7.7 (2) 8.3 (2.1) 8.1 (2.2) 0.624 (2.87) 0.538
Hunger 6.3 (2.2) 6.8 (2) 7 (1.9) 0.957 (2.87) 0.388
SD, Standard Deviation.
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Satiety Ratings
The 3-way ANCOVA for post-intervention satiety ratings,
controlled for baseline levels, revealed a significant main effect
of “group” [F(2, 83) = 11.1, p < 0.001]. Bonferroni-corrected
post hoc tests indicated significantly higher satiety ratings in
the satiety group than in the control group (p < 0.001) and in
the appetite group (p < 0.001) (Figure 3, Table 2). The 3-way
interaction between “group,” “time,” and “sex” was not significant
[Fgroup×time×sex(2, 83) = 2.5, p= 0.102].
Ghrelin Levels
The 3-way ANCOVA for post-intervention plasma ghrelin
levels, controlled for baseline levels, revealed a significant 2-way
interaction between “group” and “sex” [F(2, 71) = 3.4, p = 0.040].
Separate ANCOVAs for male and female participants indicated
a significant main effect of “group” in women [F(2,37) = 4.4,
p= 0.019] but not in men [F(2, 33) = 1.5, p= 0.235]. Bonferroni-
corrected post hoc tests indicated that the interaction in women
was due to higher post-intervention ghrelin levels in the appetite
group compared to the control group (p = 0.019; Figure 4,
Table 2). Neither the main effect of “group” [Fgroup(2, 71) = 0.9,
p= 0.401) nor the 3-way interaction between “group,” “time,” and
“sex” [Fgroup×time×sex(2, 71) = 2.7, p= 0.075] was significant.
Heart Rate
The 3-way ANCOVA for post-intervention heart rate, controlled
for baseline levels, revealed no significant main or interaction
FIGURE 2 | Hunger ratings. Baseline-corrected hunger ratings following the
three placebo interventions (estimated means ± SEM). VAS = visual analogue
scale. *p < 0.05.
effects [Fgroup(2, 82) = 0.1, p = 0.922; Fgroup×time(2, 82) = 0.2,
p= 0.812; Fgroup×time×sex(2, 82) = 1.1, p= 0.342; Table 2].
Treatment Guesses
Thirteen participants (72.2%) in the satiety group, but only five
participants (27.8%) in the appetite group guessed to having
received the active agent. The difference between groups was
significant (χ²= 0.1, p= 0.024).
DISCUSSION
This is the first study designed to evaluate the effects
of treatment-related expectations on appetite, satiety, and
associated plasma ghrelin levels. Our randomized-controlled
double-blinded experiment revealed that the satiety-enhancing
placebo intervention successfully altered subjective feelings of
appetite and satiety in the suggested direction. Furthermore, the
appetite-enhancing placebo intervention increased ghrelin levels
in women.
A recent meta-analysis of sham-controlled surgery trials
suggested that bariatric surgery for obesity is associated with
a large placebo effect on weight loss, equaling 71% of the
effect of active bariatric surgery (4). Our finding that the
satiety-enhancing placebo intervention indeed increased satiety
provides the first experimental evidence that treatment-related
expectations contribute to the success of satiety-enhancing
medical interventions.
FIGURE 3 | Satiety ratings. Baseline-corrected satiety ratings following the
three placebo interventions (estimated means ± SEM). VAS = visual analogue
scale. *p < 0.05.
TABLE 2 | Post-intervention values (baseline-adjusted) of hunger ratings, satiety ratings, plasma ghrelin levels, and heart rate.



















Hunger ratings (VAS; cm) 6.3 (0.4) 5.5 (0.5) 3.8 (0.4) 5.0 (0.5) 5.8 (0.4) 5.2 (0.5)
Satiety ratings (VAS; cm) 2.5 (0.4) 2.1 (0.4) 4.0 (0.4) 3.9 (0.4) 2.3 (0.4) 2.3 (0.4)
Plasma ghrelin levels (pg/ml) 453.5 (20.2) 535.5 (20.1) 455.6 (20.8) 478.9 (21.0) 504.1 (24.2) 452.8 (20.1)
Heart rate (1/min) 63.2 (1.7) 63.3 (1.7) 65.7 (1.7) 62.2 (1.7) 62.8 (1.7) 64.6 (1.7)
SE, Standard Error; VAS, Visual Analogue Scale.
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FIGURE 4 | Ghrelin levels in women. Baseline-corrected plasma ghrelin levels
(pg/ml) in women following the three placebo interventions (estimated means
± SEM). *p < 0.05.
The retrospective evaluation of treatment guesses suggests
that the appetite-enhancing placebo intervention was less
credible to the participants than the satiety-enhancing placebo
intervention. This could explain why the appetite-enhancing
placebo intervention did not alter subjective feelings of appetite
and satiety. However, the guess of having received placebo does
not necessarily mean that the participant did not believe in the
effectiveness of the intervention. Recent studies indicate that also
open-label placebo administration can lead to positive beliefs and
symptom improvement (23–25). Supporting this explanation, we
observed an increase in ghrelin levels following the appetite-
enhancing placebo intervention in women, suggesting the
occurrence of a placebo effect on a physiological level. Ghrelin
is secreted by the stomach, with levels peaking just before a
meal and declining after feeding. In addition, ghrelin serves
as an interoceptive signal for food-seeking behavior (26, 27).
A previous study in a predominantly female cohort (65%
women) found that plasma ghrelin levels increased when
participants anticipated the intake of an “indulgent” milk-shake
as compared to a “low-calorie” milk-shake, even though hunger
ratings did not change (7). This may indicate that ghrelin is a
highly sensitive measure to capture a psychologically mediated
increase in appetite that occurs even before behavioral effects
are measureable. With regard to the observed sex difference,
it is important to note that stronger physiological placebo
responses in women have also been reported in studies of placebo
analgesia (15, 28). In addition, there is ample evidence that the
physiology of appetite differs between sexes (29, 30). For example,
women showed higher brain activation in the fusiform gyrus
while viewing high-caloric pictures in the hungry state (31).
Furthermore, brain activation to calorie-rich foods within the
dorsolateral, ventrolateral, and ventromedial prefrontal cortices,
the middle/posterior cingulate, and the insula were larger in
women than in men (32), regions that play a role in self-
reflection (33). Interestingly, sex differences in eating behavior
are mediated, among other factors, by the gut hormone ghrelin
(14), both in terms of secretion of this hormone and of ghrelin
sensitivity (34, 35). Thus, the sex-specific ghrelin response in our
experiment is in line with previous studies showing a stronger
physiological response to placebo interventions as well as to
appetite-enhancing food stimuli in women.
Our results provide first evidence that a placebo intervention
to enhance appetite may enhance ghrelin secretion in women
even before behavioral effects are measureable. In contrast,
we found a strong effect of the satiety-enhancing intervention
on ratings of hunger and satiety, notably without changes
in circulating levels of total ghrelin. These data collectively
suggest that ghrelin secretion is most likely unrelated to
the placebo effect on satiety. It could be argued that food
ingestion is a prerequisite for the postprandial fall in circulating
ghrelin. However, as demonstrated in healthy human volunteers,
postprandial suppression of ghrelin secretion did not differ
between subjects receiving a mixed meal or who have been sham
fed to allow smelling, chewing and tasting but not swallowing
of food (26, 36). An anorexigenic hormone such as leptin or
peptide YY (37) may still be better suited to capture the hormonal
correlates of the placebo effect on satiety.
Several limitations of our results need to be mentioned.
First, the short observational period in our experiment does not
allow any conclusion on whether placebo effects on hunger and
satiety can last longer than a few hours. Second, we performed
our experiment in a normal-weight sample. Further studies are
needed to clarify whether the findings of our experiment can
be replicated in obese and anorectic patients. Third, our study
was designed to investigate placebo effects on hunger and satiety
induced by verbal suggestions. Learning mechanisms, such as
behavioral conditioning and reinforcement learning, are known
to affect eating behavior (38) as well as placebo effects (39),
and their involvement in placebo effects on appetite-regulation
should be evaluated in follow-up studies.
In conclusion, the results of the present study indicate a
powerful inhibition of appetite in response to a satiety-enhancing
placebo intervention and first evidence for an increase of
ghrelin levels in women in response to an appetite-enhancing
placebo intervention. Results thus provide the first experimental
evidence that expectations are important factors to consider
when evaluating the effects of medical interventions in the field of
appetite regulation. Further studies with additional physiological
outcome parameters are needed to better understand the
psychobiological processes triggered by appetite-modulating
placebo interventions.
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